AFFiRiS reports encouraging outcomes from clinical research of its two Alzheimer’s vaccines AFFiRiS AG today announced that the principal endpoints have already been met for the Stage I clinical research of its two Alzheimer’s vaccines AD01 and AD02, which demonstrated favourable tolerability and safety profiles clotrimazole betamethasone dipropionate cream . These total results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals. All 48 patients treated in these research were given four vaccinations that have been well tolerated and no serious side results associated with the vaccine applicants were observed. The outcomes demonstrate the potential value of the AFFITOME technology, which forms the system for both these vaccines and could create a generation of extremely specific vaccines.
Results from the study suggest that AFECTAIR may be an effective alternative to the SoC among ventilatory circuit devices used for the delivery of inhaled nitric oxide. These data reinforce our decision to expose AFECTAIR, something that exemplifies our dedication to advancing a fresh standard for respiratory important care, stated W. Thomas Amick, Discovery Labs Chairman and CEO, AFECTAIR is an example of our company’s innovative spirit and capability to identify possibly significant market opportunities as they emerge through our analysis and development efforts.